Phase 4
Completed N=54
Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
Source: ClinicalTrials.gov NCT02635828 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: PONV Incidence — 12 participants
◆ Published Evidence
Highly cited
970citations · ~42 / year
Consensus guidelines for managing postoperative nausea and vomiting.
Summary
Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 hours after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in high-risk patients, the PONV rate could be as high as 80%. Therefore, the study design of this single arm, non-randomized, pilot study assessed the efficacy and safety profile of a triple therapy combination with palonosetron, dexamethasone and promethazine to prevent PONV in patients undergoing craniotomies under general anesthesia.
Linked Publications (5)
-
Consensus guidelines for managing postoperative nausea and vomiting.
-
Which clinical anesthesia outcomes are important to avoid? The perspective of patients.
-
Prevention and treatment of postoperative nausea and vomiting.
-
A randomized, double-blinded comparison of ondansetron, droperidol, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy.
-
[Postoperative nausea and vomiting after neurosurgery (infratentorial and supratentorial surgery)].
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PONV Incidence |
12 | — |
| SECONDARY Incidence of Subjects Significant QTc Changes in the EKG |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients, 18 to 85 years of age, of any race or gender. With an American Society of Anesthesiologist (ASA) physical status of I to III who are scheduled to undergo neurological surgery requiring opening of the cranium and Dura matter under general anesthesia, at Ohio State University Medical Center and who consent in writing to participating in this study.
- Post operative hospitalization expected to last at least 72 hours.
- Subjects whose surgery is expected to require at least 1 hours of general anesthesia
- Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or who have been surgically sterilized or are postmenopausal.
Exclusion Criteria
- Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the age of 85, ASA classification of V, alcohol or drug abusers.
- Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol.
- Subjects who are breastfeeding.
- Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours prior to anesthesia or suffer chronic nausea and/or vomiting
- Subjects who have been treated with any drug or other treatment with anti-emetic efficacy within the last 24 hours prior to the start of treatment.
- Subjects who have participated in a clinical trial of an investigational drug within 30 days prior to surgery.
- Subjects who are participating in any other clinical study
Data sourced from ClinicalTrials.gov (NCT02635828) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.